Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2012 Dec 1;21(126):267-70.
doi: 10.1183/09059180.00005312.

Pulmonary arterial hypertension: bridging the present to the future

Marc Humbert, Rogerio Souza, Nazzareno Galiè, Vallerie McLaughlin, Gérald Simonneau, Lewis Rubin
Editorial

Pulmonary arterial hypertension: bridging the present to the future

Marc Humbert et al. Eur Respir Rev. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Statement of Interest

M. Humbert has relationships with drug companies including Actelion, Aires, AstraZeneca, Bayer, Bristol-Myers Squibb, GSK, Merck, Novartis, Nycomed, Pfizer, Stallergènes, TEVA and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. R. Souza has received lecture fees from Actelion, Bayer, GSK and Lilly, and has participated in advisory boards from Actelion, Bayer, Lilly and GSK. N. Galiè served as a consultant and received payment for lecture fees from Actelion Pharmaceuticals Ltd, Pfizer, GSK, Eli Lilly and Bayer Schering Pharma. V. McLaughlin has received speaking and/or consulting fees from Actelion, Bayer, Gilead and United Therapeutics. The University of Michigan has received research funding for multicentre trials from Actelion, Novartis, Pfizer and United Therapeutics. G. Simonneau has relationships with pharmaceutical companies including Actelion, Bayer HealthCare, Eli Lilly, GSK, Novartis and Pfizer. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards. L. Rubin has received consulting fees from Actelion, United Therapeutics, Bayer, GSK, Pfizer, Aires, GeNO and Gilead, and has served as an expert witness in litigation dealing with PAH.

References

    1. Benza RL, Miller DP, Gomberg-Maitland M, et al. . Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164–172. - PubMed
    1. Badesch DB, Raskob GE, Elliott CG, et al. . Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010; 137: 376–387. - PubMed
    1. Humbert M, Sitbon O, Chaouat A, et al. . Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156–163. - PubMed
    1. Humbert M, Sitbon O, Yaïci A, et al. . Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010; 36: 549–555. - PubMed
    1. Humbert M, Sitbon O, Chaouat A, et al. . Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023–1030. - PubMed

Publication types

MeSH terms